Enzalutamide + External Beam Rt For Prostate

You may not qualify if:

• Received an investigational agent within 4 weeks prior to enrollment
• Stage T4 prostate cancer by clinical examination or radiologic evaluation.
• Hypogonadism or severe androgen deficiency as defined by screening serum testosterone less than 50 ng/dL below the normal range for the institution.
• Prior androgen deprivation, chemotherapy, surgery, or radiation for prostate cancer.
• Receiving concurrent androgens, anti-androgens, estrogens, or progestational agents, or received any of these agents within the 6 months prior to enrollment or having taken finasteride or dutasteride within 30 days of registration.
• History of another active malignancy within the previous 5 years other than curatively treated nonmelanomatous skin cancer and superficial bladder cancer. Participants treated for malignancy with no relapse within two years are eligible to participate in the study.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.
• Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment.
• Unwilling to use contraceptives while on study if relevant to patient.
• History of seizure or any condition or concurrent medication that may predispose to seizure.
• History of loss of consciousness or transient ischemic attack within 12 months prior to enrollment.
• Clinically significant cardiovascular disease, including:
• Myocardial infarction within 3 months of enrollment;
• Uncontrolled angina within 3 months of enrollment;
• Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan performed within 3 months results in a left ventricular ejection fraction ≥ 45%;
• +12 more criteria